XTRA:ILM1

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany.


Snowflake Analysis

Solid track record with reasonable growth potential.

Share Price & News

How has Medios's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ILM1 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-8.8%

ILM1

-0.4%

DE Healthcare

2.2%

DE Market


1 Year Return

106.3%

ILM1

1.9%

DE Healthcare

5.6%

DE Market

Return vs Industry: ILM1 exceeded the German Healthcare industry which returned -2.6% over the past year.

Return vs Market: ILM1 exceeded the German Market which returned 3.4% over the past year.


Shareholder returns

ILM1IndustryMarket
7 Day-8.8%-0.4%2.2%
30 Day-7.2%3.7%7.3%
90 Day20.7%16.4%22.1%
1 Year106.3%106.3%2.2%1.9%7.9%5.6%
3 Year298.9%298.9%-24.4%-26.8%4.5%-3.8%
5 Yearn/a-16.4%-20.2%12.5%-2.7%

Price Volatility Vs. Market

How volatile is Medios's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Medios undervalued compared to its fair value and its price relative to the market?

31.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ILM1 (€36.2) is trading below our estimate of fair value (€53.16)

Significantly Below Fair Value: ILM1 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ILM1 is poor value based on its PE Ratio (54x) compared to the DE Healthcare industry average (25.8x).

PE vs Market: ILM1 is poor value based on its PE Ratio (54x) compared to the German market (20.9x).


Price to Earnings Growth Ratio

PEG Ratio: ILM1 is poor value based on its PEG Ratio (1.8x)


Price to Book Ratio

PB vs Industry: ILM1 is overvalued based on its PB Ratio (6.5x) compared to the DE Healthcare industry average (1.4x).


Next Steps

Future Growth

How is Medios forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

30.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ILM1's forecast earnings growth (30.1% per year) is above the savings rate (0.2%).

Earnings vs Market: ILM1's earnings (30.1% per year) are forecast to grow faster than the German market (22.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ILM1's revenue (15.4% per year) is forecast to grow faster than the German market (6% per year).

High Growth Revenue: ILM1's revenue (15.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ILM1's Return on Equity is forecast to be low in 3 years time (13.1%).


Next Steps

Past Performance

How has Medios performed over the past 5 years?

70.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ILM1 has high quality earnings.

Growing Profit Margin: ILM1's current net profit margins (1.9%) are higher than last year (1.3%).


Past Earnings Growth Analysis

Earnings Trend: ILM1's earnings have grown significantly by 70.9% per year over the past 5 years.

Accelerating Growth: ILM1's earnings growth over the past year (125.6%) exceeds its 5-year average (70.9% per year).

Earnings vs Industry: ILM1 earnings growth over the past year (125.6%) exceeded the Healthcare industry 9.7%.


Return on Equity

High ROE: ILM1's Return on Equity (12%) is considered low.


Next Steps

Financial Health

How is Medios's financial position?


Financial Position Analysis

Short Term Liabilities: ILM1's short term assets (€79.4M) exceed its short term liabilities (€28.7M).

Long Term Liabilities: ILM1's short term assets (€79.4M) exceed its long term liabilities (€6.3M).


Debt to Equity History and Analysis

Debt Level: ILM1's debt to equity ratio (3.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if ILM1's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: ILM1's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: ILM1's interest payments on its debt are well covered by EBIT (82.1x coverage).


Balance Sheet


Next Steps

Dividend

What is Medios's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ILM1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ILM1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ILM1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ILM1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ILM1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Manfred Schneider (58yo)

3.75yrs

Tenure

€227,000

Compensation

Mr. Manfred Schneider has been the Chief Executive Officer and Chairman of the Executive Board at Medios AG since October 14, 2016. Mr. Schneider is the Founder of Medios Pharma GmbH and Medios Manufaktur  ...


CEO Compensation Analysis

Compensation vs Market: Manfred's total compensation ($USD259.19K) is below average for companies of similar size in the German market ($USD1.31M).

Compensation vs Earnings: Manfred's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Manfred Schneider
Chairman of Executive Board & CEO3.75yrs€227.00kno data
Matthias Gärtner
CFO & Member of Executive Board3.75yrs€239.00kno data
Christoph Prußeit
Chief Innovation Officer & Member of Executive Board1.5yrs€185.00kno data
Mi-Young Miehler
COO & Member of Executive Board3yrs€245.00kno data

3.4yrs

Average Tenure

52yo

Average Age

Experienced Management: ILM1's management team is considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.4%.


Top Shareholders

Company Information

Medios AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medios AG
  • Ticker: ILM1
  • Exchange: XTRA
  • Founded: 2016
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: €582.277m
  • Shares outstanding: 16.08m
  • Website: https://www.medios.ag

Number of Employees


Location

  • Medios AG
  • Friedrichstrasse 113a
  • Berlin
  • Berlin
  • 10117
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ILM1DB (Deutsche Boerse AG)YesBearer SharesDEEURAug 2016
ILM1XTRA (XETRA Trading Platform)YesBearer SharesDEEURAug 2016
0QB4LSE (London Stock Exchange)YesBearer SharesGBEURAug 2016

Biography

Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products focusing on oncology, auto immunology, ophthalmology, and neurology, as well as infectious diseases. The Patient-Specific Therapies segment manufactures drugs for patients on behalf of pharmacies. The company was founded in 2016 and is headquartered in Berlin, Germany. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/15 20:56
End of Day Share Price2020/07/15 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.